Nkarta

Nkarta, Inc. is built on the proprietary, robust, and well-characterized Natural Killer (NK) cell expansion technology pioneered by Dario Campana. The company focuses on leveraging the inherently powerful capabilities of NK cells to recognize and eliminate abnormal cells while recruiting adaptive immune effectors to generate specific and long-lasting responses. Nkarta is combining its NK expansion platform technology with proprietary cell engineering techniques to develop differentiated autologous and allogeneic cell therapy candidates for cancer treatment.